Skip To Content

Study ID: Merck MK-3475-199 Keynote 199

Title:

Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy

Location:
Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Christopher Sumey, MD,Amit Panwalkar, MD,John Reynolds, MD
Disease:
Prostate
Stage:
Phase II
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.